Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Donidalorsen in healthy volunteers
NCT03263507Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Oct 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing Donidalorsen with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events related to treatment up to 176 days, Peak Plasma Concentration up to 176 days and 2 more. Started Aug 2017; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03263507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263507.